BGB-10188 + zanubrutinib

BGB-10188 + zanubrutinib is a combination of two small-molecule oral drugs in development for the treatment of mature B-cell malignancies, specifically relapsed/refractory follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). BGB-10188 is a highly selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), while zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor. The combination is being investigated based on preclinical and early clinical data suggesting synergistic anti-proliferative and anti-tumor effects via dual blockade of B-cell receptor (BCR) signaling, leading to enhanced inhibition of cellular pathways critical for malignant B cell survival and overcoming certain resistance mechanisms. Both agents are developed by BeiGene and are being studied in phase 1/2 clinical trials for B-cell malignancies[1][2][3][5][6][7].

Other names

BGB-10188 and zanubrutinibBGB10188 and zanubrutinibBGB 10188 and zanubrutinibBGB-10188 plus zanubrutinibBGB10188 plus zanubrutinibBGB 10188 plus zanubrutinib